Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IGC PharmaIGC -0.38%24 EV-to-EBITDA is -2.88 as of Jul. 25, 2026. GuruFocus rates IGC with a GF Score™ of 24/100 and a GF Value™ of $0.24 (Fairly Valued). The stock has 6 warning signs investors should review. Among 402 Biotechnology companies, IGC Pharma ranks worse than 248755.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, IGC Pharma's enterprise value is $28.24 Mil.
IGC Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-9.82 Mil. Therefore, IGC Pharma's EV-to-EBITDA for today is -2.88.
The historical rank and industry rank for IGC Pharma's EV-to-EBITDA or its related term are showing as below:
IGC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -105.76 Med: -3.57 Max: 4.38
Current: -2.88
During the past 13 years, the highest EV-to-EBITDA of IGC Pharma was 4.38. The lowest was -105.76. And the median was -3.57.
IGC's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 12.2
vs IGC: -2.88
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
IGC Pharma (AMEX:IGC) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
IGC Pharma's share price for today is $0.264.
IGC Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for IGC Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, IGC Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IGC Pharma EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IGC Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IGC Pharma's EV-to-EBITDA falls into.
IGC Pharma's current Enterprise Value is $28.24 Mil.
IGC Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.82 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (IGC) has a EV-to-EBITDA of -2.88 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IGC Pharma. According to the industry distribution chart, IGC Pharma ranks #999999 out of 402 companies in the Biotechnology industry.
Is IGC Pharma's EV-to-EBITDA too high?
IGC Pharma's current EV-to-EBITDA is -2.88. Based on the distribution chart, IGC Pharma ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IGC Pharma has a GF Score™ of 24/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's EV-to-EBITDA compare to SER and NRSN?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #999999 out of 402 companies for EV-to-EBITDA. This places IGC Pharma in the lower half of its industry. The industry median EV-to-EBITDA is 12.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.20, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on IGC Pharma. For the Biotechnology industry, the median EV-to-EBITDA is 12.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current EV-to-EBITDA is -2.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Fairly Valued. The stock's GF Value™ is $0.24, compared to a current price of $0.26 — trading 10% above its estimated fair value. The current EV-to-EBITDA is -2.88. IGC Pharma's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For IGC Pharma (IGC), the current EV-to-EBITDA is -2.88 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IGC Pharma (IGC) Overvalued in 2026?
Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued.
The current stock price of $0.26 is trading 10% above its estimated GF Value™ of $0.24.
GuruFocus considers IGC Pharma to be Fairly Valued.
Key valuation signals for IGC:
EV-to-EBITDA: -2.88
GF Value™: $0.24 vs. price of $0.26 (10% above fair value)
No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
24GF Score
Get the complete analysis for IGC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IGC has been successfully added to your 
